Market capitalization | $4.46b |
Enterprise Value | $4.34b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 21.74 |
P/S ratio (TTM) P/S ratio | 22.32 |
P/B ratio (TTM) P/B ratio | 17.73 |
Revenue growth (TTM) Revenue growth | 71.71% |
Revenue (TTM) Revenue | $199.84m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a PROCEPT BioRobotics forecast:
11 Analysts have issued a PROCEPT BioRobotics forecast:
Sep '24 |
+/-
%
|
||
Revenue | 200 200 |
72%
72%
|
|
Gross Profit | 110 110 |
90%
90%
|
|
EBITDA | -101 -101 |
1%
1%
|
EBIT (Operating Income) EBIT | -106 -106 |
2%
2%
|
Net Profit | -100 -100 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Reza Zadno |
Employees | 626 |
Founded | 2007 |
Website | www.procept-biorobotics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.